

## AIMS

The International Cancer Vaccine Conference is intended to gather virologists, immunologists, vaccinologists, oncologists, molecular biologists, for a multidisciplinary approach to chronic viral infections and cancer. New avenues are related to identification of new antigenic epitopes and optimal strategies of presentation and delivery. International regulatory strategies for bio-molecular therapeutic approaches will be discussed.

### Scientific and Organizing Committee:

Ist. Naz. Tumori "Fond. Pascale" (INT-NA) - Naples, Italy

**F.M. Buonaguro**

**L. Buonaguro**

**M.L. Tornesello**

Soc. Ital. Virol. (SIV) - Padua, Italy

**G. Palù**

Inst. of Human Virology (IHV) - Baltimore, USA

**G. Lewis**

### Web page:

[http://wpage.unina.it/irccsvir/congress/vaccinecongress\\_naples2006/index.html](http://wpage.unina.it/irccsvir/congress/vaccinecongress_naples2006/index.html)

[http://www.cancervaccine\\_naples2006.unina.it/](http://www.cancervaccine_naples2006.unina.it/)



INT-NA "Fond. G. Pascale"



## International Cancer Vaccine Conference: vaccines and immunotherapies for chronic viral infections and malignancies.

May 26-28 2006

Naples - ITALY



C  
A  
N  
C  
E  
R  
V  
A  
C  
C  
I  
N  
E  
C  
O  
N  
F  
E  
R  
E  
N  
C  
E  
  
N  
A  
P  
L  
E  
S  
  
2  
0  
0  
6

## Sessions

- **Epidemiology of cancer and virus-associated malignancies;**
- **Virus and Cancer;**
- **From chronic infections to Cancer;**
- **Targeting Viral/Tumor Antigens;**
- **Approaches to Immunotherapy and clinical trials;**
- **New strategies in Cancer targeting;**
- **New avenues for Vaccine Developments;**
- **Adjuvants for the development of vaccines;**
- **Dendritic Cells;**
- **Modulation of Immunity in vaccine strategies;**
- **Regulatory Issues in clinical trials.**

## Selected Issues

Cancer epidemiology and viral burden;  
RNA and DNA Viruses and Cancers;  
Hepatitis Viruses and HCC;  
Endogenous Retroviruses (HERV) and Cancers;  
Cellular immunity in acute vs chronic viral infection;  
Genomic/proteomic profiling for antigen discovery;  
Cellular antigens as target for cancer vaccines;  
HPV VLPs and vaccine development;  
Peptide & subunits vaccines;  
Vaccines targeting EBV positive malignancies;  
Critical issues in cancer vaccine development;  
Overcoming the tumour challenge to cancer vaccines by focusing on premalignant disease;  
DNA Vaccines;  
Viral Vaccines;  
Structured particle vaccines;  
Ribozymes and antisense ODN for viral/cancer targeting;  
siRNAs for cancer targeting;  
Telomerase antigen in immunotherapy;  
Development of edible vaccines for humans;  
IFN and cytokines as adjuvants;  
CpG and TLRs as adjuvants;  
Mucosal adjuvants;  
Dendritic cell-based vaccination against cancer;  
Exploiting the intentional induction of autoimmune reactivity to treat metastatic disease;  
Strategies to overcome cancer-induced T regulatory cell inhibitory activity;  
Immunodominance and Immunodomination;  
Cancer escape mechanisms as strategy for immunotolerance;  
In-vitro prediction of T cell response;  
Evaluation of cancer immunotherapy by microarrays;  
Regulatory issues.

## Provisional list of invited Speakers/Chairmen

**R. Ahmed,** Emory University, School of Medicine Atlanta, USA  
**J. Bancheau,** Baylor Inst for Immunol Research Waco, Texas, USA  
**F. Belardelli,** ISS, Rome – Italy  
**U. Bertazzoni,** Univ di Verona, Verona - Italy  
**J.A. Berzofsky,** NCI, NIH, Bethesda, USA  
**E.H. Blackburn,** Univ. of California, USA  
**F.M. Buonaguro,** INT-NA, Napoli – Italy  
**L. Buonaguro,** INT-NA, Napoli – Italy  
**G. Castello,** INT-NA, Napoli – Italy  
**V. Cerundolo,** Univ. of Oxford, Oxford, UK  
**L. Chieco-Bianchi,** Univ. Padua, Padua – Italy  
**G. Ciliberto,** IRBM, Pomezia – Italy  
**P. Coursaget,** Faculte de Pharmacie, Tours, France  
**B. Cullen,** Duke Univ., Durham, USA  
**A. Dalgleish,** St George's Hospital Medical School, London, UK  
**B. Davis,** Med & Healthcare products Regulatory Agency, UK  
**P.P. Di Nocera,** Medical School, Univ. "Federico II", Napoli – Italy  
**J. Di Paolo,** NIH, Bethesda, USA  
**E. Di Salvo,** Scientific Director, INT-NA, Napoli – Italy  
**S. Ferrone,** Roswell Park Cancer Institute, Buffalo, USA  
**S. Franceschi,** IARC, Lyon, France  
**R.C. Gallo,** Insitute of Human Virology, Baltimore, USA  
**D.A. Galloway,** FHCRC, Seattle, USA  
**E. Garaci,** ISS, Rome – Italy  
**A. Giordano,** Temple Univ., Philadelphia, USA  
**M. Glennie,** Univ. of Southampton, Southampton, UK  
**L. Harmison,** USA  
**J. Hinkula,** Karolinska Inst., Stockholm, Sweden  
**A. Itkes,** Peoples` Friendship Univ., Moscow, Russia  
**H. Koprowski,** Tomas Jefferson Univ., Philadelphia, USA  
**A. Kozlov,** St Petersburg, Russia  
**A.M. Krieg,** Coley Pharmaceutical Group, USA  
**G.K. Lewis,** Insitute of Human Virology, Baltimore, USA  
**D. Lowy,** NCI, NIH, Bethesda, USA  
**P. Maliga,** Rutgers University Piscataway, Piscataway, NJ, USA  
**F. Manca,** Univ. of Genova, Genova - Italy  
**F.M. Marincola,** NIH, Bethesda, USA  
**D. Maxwell Parkin,** Oxford University, Oxford, UK  
**C. Melief,** University Hospital Leiden, Leiden, NL  
**L. Monti,** IGV, Portici – Italy  
**F. Olivera,** Univ. of Pittsburgh, Pittsburg, USA  
**G. Palù,** President SIV, Dean Medical School, Univ Padua, Padova – Italy  
**O. Perrella,** Infectious Disease "Cotugno" Hospital, Napoli – Italy  
**R.H. Purcell,** NIH, Bethesda, USA  
**R. Rappuoli,** Chiron, Siena – Italy  
**A. Rickinson,** Univ. of Birmingham, Birmingham, UK  
**F. Rossano,** Medical School, Univ. "Federico II", Napoli – Italy  
**T. Russo,** Medical School, Univ. "Federico II", Napoli – Italy  
**F. Salvatore,** Medical School, Univ. "Federico II", Napoli – Italy  
**J. Samuel,** Univ. of Alberta, Alberta , Canada  
**M. Santangelo,** President INT-NA, Napoli – Italy  
**J. Schlom,** NCI, NIH, Bethesda, USA  
**U. Schröder,** Eurocine AB, Stockholm, Sweden  
**G. Schuler,** Univ. of Erlagen, Erlagen, Germany  
**B. Seliger,** Univ. of Mainz, Mainz , Germany  
**R. Steinman,** Rockefeller Univ., New York, USA  
**G. Tarro,** Infectious Disease "Cotugno" Hospital, Napoli – Italy  
**G. Vecchio,** Medical School, Univ. "Federico II", Napoli – Italy  
**R. Vile,** Mayo Clinic, USA  
**J. Weber,** University of Southern California, USA  
**B. Wharen,** Karolinska Inst., Stockholm, Sweden  
**H. Wigzell,** Karolinska Institutet, Stockholm – Sweden  
**S. Zappacosta,** Medical School, Univ. "Federico II", Napoli – Italy  
**H. zur Hausen,** Cancer Centrum, Heidelberg, Germany